David R. Gandara, MD

Articles

Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC

July 23rd 2021

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

January 14th 2021

David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.

Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer

August 3rd 2020

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

Dr. Gandara on Measuring TMB in NSCLC

July 28th 2020

David R. Gandara, MD, discusses measuring tumor mutational burden in patients with non–small cell lung cancer who received prior immunotherapy.

Dr. Gandara on the Utility of TMB in NSCLC

July 23rd 2020

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

Dr. Gandara on Practice-Changing Studies in Lung Cancer

October 13th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, a 2017 Giant of Cancer Care in Lung Cancer®, discusses practice-changing studies in lung cancer.

Dr. Gandara on Treatment Options for Squamous Cell NSCLC

August 20th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, 2017 Giant of Cancer Care in Lung Cancer, discusses treatment options for patients with squamous cell non–small cell lung cancer.

Dr. Gandara Discusses the OAK Trial for Lung Cancer

December 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discussed the OAK study design for patients with lung cancer.

Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

October 16th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Gandara on the MYSTIC Trial for Lung Cancer

August 25th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care

September 23rd 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Gandara on Recent Advancements in Field of Lung Cancer

August 6th 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

Dr. Gandara Discusses Third-Generation EGFR TKIs

August 11th 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Dr. Gandara Spotlights the Giants of Cancer Care

July 26th 2013

David R. Gandara, MD, from the UC Davis Cancer Center, discusses the 2013 recipient of the Giants in Cancer Care award in the field of thoracic oncology: Thomas J. Lynch, Jr., MD.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Dr. Gandara on Patient Selection for Molecular Testing

September 12th 2012

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Dr. Gandara Discusses Molecular Testing for NSCLC

August 9th 2012

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer